Research programme: anti-adrenomedullin monoclonal antibodies - Adrenomed

Drug Profile

Research programme: anti-adrenomedullin monoclonal antibodies - Adrenomed

Latest Information Update: 19 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adrenomed
  • Class Monoclonal antibodies
  • Mechanism of Action Adrenomedullin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Septic shock

Most Recent Events

  • 19 Dec 2016 Development of monoclonal antibody therapies still ongoing for Sepsis and Septic shock (Adrenomed website, December 2016)
  • 19 Dec 2016 Adrenomed has issued and pending patents for anti-adrenomedullin antibodies in Europe and USA (Adrenomed website, December 2016)
  • 02 Jan 2013 Preclinical trials in Septic shock in Germany (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top